What it is
Bremelanotide is a peptide that activates melanocortin receptors in the brain, which are involved in sexual desire. It was developed from Melanotan II.
It is used as needed before sexual activity. Researchers think it works on brain pathways linked to desire rather than on blood flow.
US regulatory status
FDA-approved (Vyleesi) in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (low sexual desire that causes distress and is not due to another condition, medicine or relationship issue). It is not approved for men or for other uses.
What the research shows
Two phase 3 trials (RECONNECT) showed small but statistically significant improvements in desire and less distress compared with placebo. It did not significantly increase the number of satisfying sexual events.
How it is given
Subcutaneous injection (single-dose autoinjector)
Commonly reported side effects
- Nausea
- Flushing
- Injection site reactions
- Headache
- Vomiting
- Darkening of skin patches (with repeated use)
Questions to ask your provider
- Could something else, like a medicine or health condition, be affecting my desire?
- Is my blood pressure safe for using bremelanotide?
- What can I do about nausea if it happens?